CEE + MPA for women who have not used MHT before. These treatments might not prevent chronic disease, as anticipated when the WHI studies were designed, but they do alleviate major symptoms and improve quality of life. With the availability of formulations that confer even more favourable safety profiles than those studied in WHI, such as nonoral estrogen, progesterone and bazedoxifene plus CEE, 10 MHT should be considered for all highly symptomatic women at menopause.
2 However, many consider bariatric surgery as a draconian last resort for T2DM management, 3 owing partly to surgical risks and because long-term efficacy rates have been uncertain. A new study by Brethauer and colleagues adds to our knowledge about the efficacy and durability of bariatric surgery effects on T2DM remission. 4 Although T2DM improved in the majority of patients undergoing bariatric surgery, recurrence after initial remission was observed in 19% over 6 years, particularly in those with prolong ed disease duration.
Lifestyle modification, weight loss and medical therapies are the foundation of disease management for T2DM. Yet weight loss is difficult to achieve and sustain in the long term, and progressive hyperglycaemia requiring additional medication use is common. Emerging data over the past several years have demonstrated that bariatric surgery provides an additional therapeutic option, particularly in indivi duals early in the course of T2DM. Bariatric surgeries lead to substantial and sustained weight loss for most patients, with the magnitude varying according to the procedure performed. For example, the Swedish Obesity Subjects (SOS) study, a long-term, prospective, controlled trial, demonstrated a mean weight loss in surgical patients of 23% after 2 years, which was sustained at 18% by 20 years. 5 In comparison, matched controls receiving usual medical care had no significant weight change over the same interval.
Furthermore, bariatric surgery was associated with improvements in obesity-related comorbidities, including hypertension and dyslipidaemia, and reduced incidences of myocardial infarction (29%), stroke (34%) and cancer in women (42%). 5 Up to 80% of individuals with T2DM at the time of surgery show improved glycaemic control or achieve disease remission, that is, normal glucose levels without the use of medication. The efficacy of bariatric surgery to improve T2DM is particularly notable for those with short disease duration (<5 years from diagnosis) and/or in those who preoperatively require only oral medication, suggesting the importance of residual β-cell function for optimal clinical response rates. Moreover, those without T2DM at the time of surgery have a 73% reduction in incident diabetes mellitus, 5 and 30-40% reductions in overall mortality can be seen in patients with obesity. 5, 6 When performed at centres of excellence, these health benefits are achieved with low operative mortality rates, ranging from 0.1% to 0.5%; 7 with the risk of long-term intestinal and nutritional complications varying depending on the procedure performed.
Brethauer and co-workers assessed the clinical outcomes of 217 patients with T2DM who had undergone Roux-en-Y gastric bypass (n = 162), gastric banding (n = 32) or sleeve gastrectomy (n = 23) after a median follow-up of 6 years (range 5-9 years). On average, patients lost 55% of excess weight during this interval. In paral lel, 24% of patients achieved complete remission, defined as normal measures of glycaemia (HbA 1c <6.0%, fasting glucose <5.6 mmol/l), and 26% achieved partial remission (HbA 1c 6.0-6.4%, fasting glucose 5.6-6.9 mmol/l), sustained for at least 1 year in the absence of diabetes medications. An additional 34% had a reduction in HbA 1c >1% but still required medication. Thus, T2DM improved in 84% of patients undergoing bariatric surgery. Moreover, patients were 3.6-fold and 1.4-fold more likely to achieve blood pressure and lipid goals, respectively, and had a 7% decrease in Framingham 10-year cardiovascular risk scores-a 25% relative improvement from baseline. Furthermore, the study demonstrates a regression in early diabetic nephropathy, as indicated by reduced serum creatinine and urinary albumin levels in 53% of study participants. However, T2DM recurred in 19% of study participants with initial remission.
As T2DM is widely recognized to be a progressive disorder, it is not surprising that initial disease remission is not sustained for all patients. Diabetes mellitus can recur in about 20-30% of patients who initially achieve remission over 5 years after bariatric surgery, 4, 8 with increased recurrence over time. Conversely, two-thirds remain in remission over 5 years. Fewer than 20% of those with initial remission remain in remission by 20 years. 9 Brethauer et al. and others demonstrate that diabetes duration and weight regain are major contributors to diabetes relapse in this setting. Interestingly, prolonged periods of glycaemic control early in T2DM are associated with continued reduction in the risk of long-term complications, including myocardial infarction and death. 10 Novel data from the SOS study suggest this 'metabolic memory' can also be observed in patients with T2DM in response to bariatric surgery, as demonstrated by progressive reduction in the relative risk of hospitalizations for diabetes-related complications in the surgical compared with the control patient groups. 9 For effective health-care delivery, physicians must be aware of the substantial metabolic benefits that can be gained from bariatric surgery, especially for the patient with T2DM, and balance this with the short-term and long-term procedural risks (Table 1) . Furthermore, the clinician must gain an understanding of the patient's perspective on their illness and individual values, cultures and preferences when counselling about therapeutic options. Individual risk tolerance and ability to adhere to lifestyle recommendations and often complex medication regimens must be considered. Although many pharmacological agents are approved for diabetes mellitus or weight management, long-term efficacy and adverse effects of these drugs remain uncertain. Engaging in discussion of these risk-benefit issues is important for a successful doctor-patient relationship and leads to the individualization of the therapeutic approach, both broadly for surgical compared with nonsurgical options and specifically for the procedure to be performed when surgical options are appropriate.
Limitations of the study by Brethauer and colleagues include the retrospective design with lack of randomization and medical comparison group, a mixture of surgical procedures (predominance of RYGB), loss at follow-up of 20% of the index population, insufficient study size for characterization of cardiovascular and mortality outcomes, and absence of assessment of adverse health outcomes related to surgery. Nevertheless, the findings add to a growing body of work 8, 9 on the long-term effectiveness and durability of bariatric surgery. Studies that evaluate the long-term outcomes of patients with T2DM undergoing bariatric surgery will continue to provide insights on ways to optimize health and help to guide clinical decision-making for both patients and health-care providers. 
